Novartis's Kymriah Comes Up Short In NHL Study
Rivals Yescarta And Breyanzi Have Succeeded In Similar Trials
Executive Summary
The BELINDA study investigating Kymriah as second-line treatment in aggressive B-cell non-Hodgkin lymphoma has missed its primary endpoint, thwarting Novartis's hopes of getting the CAR-T therapy into earlier-stage use.
You may also be interested in...
Novartis Debuts Rapidly Manufactured Autologous CAR-Ts
The company presented early data on two candidates at the ASH meeting that use a less than two-day manufacturing process, YTB323 in diffuse large B-cell lymphoma and PHE885 in multiple myeloma.
Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL
Data at ASH show CAR-T therapies may replace standard of care in an earlier line of large B-cell lymphoma with similar response rates and event-free survival for Kite’s established Yescarta and Bristol’s newer Breyanzi.
Bristol's Breyanzi, Off To A ‘Good Start,’ Shows Efficacy In Earlier Lymphoma Setting
The CAR-T therapy met the primary endpoint of improvement in event-free survival in a Phase III trial evaluating Breyanzi as a second-line alternative to stem cell transplant in large B-cell lymphoma.